Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Editas Medicine Inc’s stock clocked out at $1.21, down -0.82% from its previous closing price of $1.22. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 2.16 million shares were traded. EDIT stock price reached its highest trading level at $1.25 during the session, while it also had its lowest trading level at $1.15.
Ratios:
To gain a deeper understanding of EDIT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.75 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.13.
Stifel Downgraded its Buy to Hold on December 13, 2024, whereas the target price for the stock was revised from $11 to $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’24 when O’Neill Gilmore Neil sold 1,618 shares for $2.08 per share. The transaction valued at 3,361 led to the insider holds 312,106 shares of the business.
Mei Baisong sold 541 shares of EDIT for $1,124 on Dec 03 ’24. The EVP, CHIEF MEDICAL OFFICER now owns 133,354 shares after completing the transaction at $2.08 per share. On Sep 04 ’24, another insider, Mei Baisong, who serves as the EVP, CHIEF MEDICAL OFFICER of the company, sold 518 shares for $3.42 each. As a result, the insider received 1,774 and left with 133,895 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 99883200 and an Enterprise Value of -126716800. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.62 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at -2.052 whereas that against EBITDA is 0.569.
Stock Price History:
The Beta on a monthly basis for EDIT is 1.94, which has changed by -0.84825873 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $11.58, while it has fallen to a 52-week low of $1.12. The 50-Day Moving Average of the stock is -36.40%, while the 200-Day Moving Average is calculated to be -69.42%.
Shares Statistics:
It appears that EDIT traded 2.68M shares on average per day over the past three months and 2583580 shares per day over the past ten days. A total of 82.54M shares are outstanding, with a floating share count of 81.78M. Insiders hold about 0.93% of the company’s shares, while institutions hold 68.00% stake in the company. Shares short for EDIT as of 1735603200 were 18207713 with a Short Ratio of 6.79, compared to 1732838400 on 16060625. Therefore, it implies a Short% of Shares Outstanding of 18207713 and a Short% of Float of 27.939999999999998.
Earnings Estimates
The current rating of Editas Medicine Inc (EDIT) is the result of assessments by 14.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.39 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$2.2 and -$3.2 for the fiscal current year, implying an average EPS of -$2.69. EPS for the following year is -$1.58, with 14.0 analysts recommending between -$0.76 and -$3.31.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $34.52M. It ranges from a high estimate of $97M to a low estimate of $60k. As of the current estimate, Editas Medicine Inc’s year-ago sales were $60.05MFor the next quarter, 14 analysts are estimating revenue of $632.2k. There is a high estimate of $1M for the next quarter, whereas the lowest estimate is $61k.
A total of 15 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $97M, while the lowest revenue estimate was $1.77M, resulting in an average revenue estimate of $38.53M. In the same quarter a year ago, actual revenue was $78.12M
